Navigation Links
ACNP: Novel NMDA receptor modulator significantly reduces depression scores within hours
Date:12/6/2012

HOLLYWOOD, FL and EVANSTON, IL, December 6, 2012 -- Naurex Inc., a clinical stage company developing innovative treatments to address unmet needs in psychiatry and neurology, today reported positive results from a Phase IIa clinical trial of its lead antidepressant compound, GLYX-13. GLYX-13 is a novel partial agonist of the NMDA receptor. The Phase Ila results are being presented this week at the 51st Annual Meeting of the American College of Neuropsychopharmacology (ACNP).

The Phase IIa results show that a single administration of GLYX-13 produced statistically significant reductions in depression scores in subjects who had failed treatment with one or more antidepressant agents. The reductions were evident within 24 hours and persisted for an average of seven days. Importantly, the effect size, a measure of the magnitude of the drug's antidepressant efficacy, observed at 24 hours and at seven days after a single administration of GLYX-13, was nearly double the effect size seen with most other antidepressant drugs after 4-6 weeks of repeated dosing.

In the Phase IIa trial, GLYX-13 was well tolerated. Reported side effects were mild to moderate and were consistent with those observed in subjects receiving placebo. Consistent with previous studies, GLYX-13 did not produce any of the schizophrenia-like psychotomimetic effects associated with other drugs that modulate the NMDA receptor.

"These data are an important step in validating Naurex's mission of developing breakthrough therapies for depression and other CNS disorders," said Derek Small, CEO of Naurex. "Our founder discovered a new class of drugs that appeared to have the remarkable antidepressant efficacy of ketamine-like compounds, but without their limiting side effects. These Phase II results suggest that this discovery may translate into measurable health improvements for individuals with depression, which bodes well for the future success of GLYX-13 and the other p
'/>"/>

Contact: Barbara Lindheim
blindheim@bllbiopartners.com
917-355-9234
BLL Partners, LLC
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Scripps Florida scientists uncover a novel cooperative effort to stop cancer spread
2. Novel mechanism through which normal stromal cells become cancer-promoting cells identified
3. Novel breast screening technology increases diagnostic accuracy
4. UNC, Vanderbilt discover a new live vaccine approach for SARS and novel coronaviruses
5. Moffitt Cancer Center researchers identify novel metabolic programs driving aggressive brain tumors
6. Novel treatment strategies for epilepsy
7. Taiho Pharmaceutical unveils data on 8 novel anticancer compounds
8. Researchers ID potential patient population who may benefit from novel anti-platelet treatment
9. Undertreatment of common heart condition persists despite rapid adoption of novel therapies
10. Moffitt cancer center researchers find novel predictor for MDS progression risk
11. Novel surgery removes rare tumor, rebuilds face and jaw
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... 2014 Kirklyn Smith, an office manager for ... a new world’s record by walking 5,000 miles in a ... constantly amazed by the thousands of individual stories of TrekDesk ... to stand out more than the others. , Kirklyn has ... count which tallies a range of 54,823 steps (presumably on ...
(Date:8/28/2014)... (HealthDay News) -- Lack of sleep not only puts teens ... increased risk for obesity, researchers warn. The study authors ... were aged 16 and 21. Nearly one-fifth of them got ... were age 16, and this group was 20 percent more ... got more than eight hours of sleep per night at ...
(Date:8/28/2014)... (PRWEB) August 28, 2014 NJ ... Institute of North Jersey. , NJ Top Doc, ... is now a certified medical examiner for the ... certified by the department to perform all drug ... training in diagnosing and treating musculoskeletal disorders including ...
(Date:8/28/2014)... In 2012, The Ben & Catherine Ivy Foundation ... brain cancer research projects at the Translational Genomics ... officially received the final regulatory approval from University ... for the trial can begin. , In the ... Trial," TGen and its clinical partners will lead ...
(Date:8/28/2014)... August 28, 2014 As Mirena IUD ... around the U.S., Bernstein Liebhard LLP notes that a ... like Mirena as ideal birth control for teenage girls. ... authors of the study point out that IUDs are ... other methods favored by this patient population. Their study, ...
Breaking Medicine News(10 mins):Health News:There are many reasons why Americans' exercise levels have declined - Meet an executive that refuses to sit still with his TrekDesk Treadmill Desk even in a sedentary job 2Health News:Less Sleep in Teen Years Tied to More Pounds at 21 2Health News:NJ Top Docs Presents Dr. Christophe Oliveira of Rehabilitation Instiute of North Jersey 2Health News:NJ Top Docs Presents Dr. Christophe Oliveira of Rehabilitation Instiute of North Jersey 3Health News:TGen receives approval for patient enrollment in brain cancer clinical trial 2Health News:Mirena IUD Lawsuit News: Bernstein Liebhard LLP Notes New Study Touting IUDs as Ideal Birth Control for Teenage Girls 2Health News:Mirena IUD Lawsuit News: Bernstein Liebhard LLP Notes New Study Touting IUDs as Ideal Birth Control for Teenage Girls 3Health News:Mirena IUD Lawsuit News: Bernstein Liebhard LLP Notes New Study Touting IUDs as Ideal Birth Control for Teenage Girls 4
... HOUSTON, Feb. 2, 2009 Stuart Dryer, the John and ... chair at the University of Houston, has been awarded the ... of Science (AAAS). AAAS is the world,s ... have made distinguished contributions to the advancement of science. ...
... Feb. 2, 2010 News media and others interested ... next in a series of American Chemical Society (ACS) ... variety of pertinent career topics impacting science and engineering ... p.m. Eastern Time, the free webinar will feature Carolyn ...
... that tension on DNA molecules can affect gene expression---the process ... what to do. Scientists understand the chemistry involved ... The U-M group is believed to be the first to ... Their paper is published in the current edition of ...
... Government ... in which he will oversee all of the publisher’s editorial and commercial operations. , ... Washington, DC (PRWEB) Feb. 4, 2010 ... General Manager, a role in which he will oversee all of the publisher’s editorial and ...
... ... to Stay Awake and Alert , ... Jackson, CA (PRWEB) February 2, 2010 -- 5150 Juice (5150juice.com) today announced a handy ... up to 500mgs per ounce of caffeine to turn any drink into a Super Energy ...
... Former ... StatCom in a strategic partnership program that helps hospitals transform throughput operations. , ... Atlanta, GA (PRWEB) February ... MBA, to the StatCom transformation team as enterprise vice president, Western region. Previously, Thalken ...
Cached Medicine News:Health News:Biology professor becomes 5th at UH to reach prestigious AAAS status 2Health News:ACS webinar features tips for finding and building a career in the food and flavor industries 2Health News:Mechanical forces could affect gene expression 2Health News:Government Executive Media Group Completes Leadership Search 2Health News:Government Executive Media Group Completes Leadership Search 3Health News:5150 Juice Launches Pocket-Sized Syringe Containing 166.6mg of Liquid Caffeine for Consumers to Add To Their Favorite Drink 2Health News:5150 Juice Launches Pocket-Sized Syringe Containing 166.6mg of Liquid Caffeine for Consumers to Add To Their Favorite Drink 3Health News:Mary Kay Thalken Joins StatCom as Enterprise VP, Western Region 2Health News:Mary Kay Thalken Joins StatCom as Enterprise VP, Western Region 3
(Date:8/28/2014)... Aug. 28, 2014  In recognition of the increased ... from the flu, pneumonia, shingles and other illnesses, ... declared September to be Senior Vaccination Month. Because ... is important that adults ages 65 years and ... CVS pharmacists and MinuteClinic nurse practitioners and physician ...
(Date:8/28/2014)... , Aug. 28, 2014 /PRNewswire/ ... market research report is available in ... Therapeutics in Asia-Pacific Markets to 2020 ... Unmet Need in Newly Diagnosed and ... http://www.reportlinker.com/p02343492/Glioblastoma-Multiforme-Therapeutics-in-Asia-Pacific-Markets-to-2020---Novel-Therapeutic-Approaches-Target-High-Unmet-Need-in-Newly-Diagnosed-and-Recurrent-GBM.html Glioblastoma ...
(Date:8/28/2014)... , Aug. 28, 2014 Telik, Inc. ... company that merged with MabVax Therapeutics, Inc. on ... significant progress related to the development of its ... was recovered using the Company,s internally developed antibody ... potential for multiple antibody based therapeutic and diagnostic ...
Breaking Medicine Technology:September is Senior Vaccination Month at CVS/pharmacy and MinuteClinic 2September is Senior Vaccination Month at CVS/pharmacy and MinuteClinic 3September is Senior Vaccination Month at CVS/pharmacy and MinuteClinic 4Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 2Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 3Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 4Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 5Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 6Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 7Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 8Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 9Telik Reports Progress Toward Multiple Early Stage Milestones in the Development of a Novel Antibody-based Therapeutic Agent for Gastrointestinal Cancers 2Telik Reports Progress Toward Multiple Early Stage Milestones in the Development of a Novel Antibody-based Therapeutic Agent for Gastrointestinal Cancers 3Telik Reports Progress Toward Multiple Early Stage Milestones in the Development of a Novel Antibody-based Therapeutic Agent for Gastrointestinal Cancers 4
The Biopro All Poly cup is a uniquely designed UHMWPE acetabular cup....
The Pe-Plus offers an additional clinical option for replacing the acetabulum....
BatCup cotyloid implant, designed for use in revision surgery, is an hemispherical metal cup, with grooves on the edges that house locking flanges, which are attached to the iliac bone by cancellous ...
The cementless acetabular shells form part of the Mallory head range of femoral and acetabular implants....
Medicine Products: